Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma

2003 ◽  
Vol 58 (4) ◽  
pp. 428-435 ◽  
Author(s):  
Maurice J. H. M. Pluijmen ◽  
Carmen Eustatia-Rutten ◽  
Bernard M. Goslings ◽  
Marcel P. Stokkel ◽  
Alberto M. Pereira Arias ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Ablation Therapy

scholarly journals Clinical, Pathological, Treatment Pattern and Post-management Follow-up Features of Differentiated Thyroid Carcinoma (DTC) in a Tertiary Level Health Care Center of Bangladesh

2020 ◽  
Vol 32 (1) ◽  
pp. 25-28
Author(s):  
Parvez Ahmed ◽  
Subrata Ghosh ◽  
Mostafa Shamim Ahsan ◽  
Nasrin Begum ◽  
Mosharruf Hossain ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Thyroid Nodules ◽  
Care Center ◽  
Differentiated Thyroid Carcinoma ◽  
Treatment Pattern ◽  
College Hospital ◽  
Ablation Therapy ◽  
Health Care Center ◽  
Radioiodine Ablation

Introduction: This study evaluates clinical, pathological, treatment pattern and post-management follow-up features of differentiated thyroid carcinoma affected patients who had attended Rajshahi Medical College Hospital as well as private clinics and then Institute of Nuclear Medicine & Allied Sciences, Rajshahi for primary surgical management and post-operative radioiodine ablation therapy respectively. Materials and Methods: It is a retrospective study. Clinico-pathological, treatment and post-management follow-up features of 254 patients of histologically proved differentiated thyroid carcinoma (DTC) were recorded from their ultrasonography report, pre-operative cytology, operation note, post-operative histopathology and radioiodine ablation therapy related follow-up book between 2011 and 2015 and analyzed using statistical software IBM SPSS v. 16. Results: Among the sample (n=254), 211 (83 %) were female and 43 (17 %) were male. Mean age group was 30-39 years. In relation to FNAC findings of thyroid nodules among this study sample (n=254), 223 (88%) had malignant cytology, 16 (6%) had borderline cytology and 15 (6%) had benign cytology. Regarding the histopathological findings of thyroid nodules, 241 (95 %) had papillary carcinoma and 13 (5 %) had follicular carcinoma. Regarding radioiodine ablation dose, 198 (78%) had been given 138 millicurie (5.1 gigabecquerel) and 56 (22%) had been given 178 millicurie (6.6 gigabecquerel). Conclusion: Early and successful management of differentiated thyroid carcinoma is required to practice widely and equitably in order to significantly reduce mortality and morbidity related to such conditions. Medicine Today 2020 Vol.32(1): 25-28

scholarly journals Comparison of the late effects of ablation therapy with single and fractionated dose of radioiodine in patients with differentiated thyroid carcinoma

2016 ◽  
Author(s):  
Kosma Wolinski ◽  
Rafal Czepczynski ◽  
Adam Stangierski ◽  
Maciej Trojanowski ◽  
Magdalena Rewaj-Losyk ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Late Effects ◽  
Differentiated Thyroid Carcinoma ◽  
Ablation Therapy

scholarly journals Malignant Struma Ovarii: Good Response after Thyroidectomy and 131I Ablation Therapy

2008 ◽  
Vol 2 ◽  
pp. CMO.S410 ◽  
Author(s):  
Erica W.M. Janszen ◽  
Helena C. Van Doorn ◽  
Patricia C. Ewing ◽  
Ronald R. De Krijger ◽  
Johannes H.W. De Wilt ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Metastatic Carcinoma ◽  
Surgical Removal ◽  
Struma Ovarii ◽  
Nuclear Medicine Imaging ◽  
Ablation Therapy ◽  
Malignant Struma Ovarii ◽  
Primary Surgery ◽  
Well Differentiated

Background Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. Cases We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and 131I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease. Conclusion Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine (131I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine (123I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential.

Clinical evaluation of a new thyroglobulin immunoradiometric assay in the follow-up of differentiated thyroid carcinoma

2003 ◽  
Vol 42 (02) ◽  
pp. 71-77 ◽  
Author(s):  
I. Schreivogel ◽  
C. Angerstein ◽  
U. Siefker ◽  
K. Lehmann ◽  
G. Altenvoerde ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Residual Disease ◽  
False Negative ◽  
Differentiated Thyroid Carcinoma ◽  
Threshold Concentration ◽  
High Rate ◽  
Functional Assay ◽  
Hypothyroid Patient ◽  
Assay Sensitivity ◽  
Significant Difference

SummaryAim: Formal and clinical comparison of a new 3rd-gene-ration-Tg-IRMA (3-G-IRMA; Dynotest®Tg-plus) with a conventional Tg-IRMA (3-G-IRMA; SELco®Tg-assay) for patients with differentiated thyroid carcinoma. In addition we evaluated, if thyroglobulin (Tg) levels above a specific threshold concentration indicate the need for further investigations for residual disease. Patients, methods: Tg concentration of 105 sera of 93 consecutive patients with a differentiated thyroid cancer was determined with both assays and compared at different cut-off values (Dynotest®Tg-plus: 0.2, 1, 2 ng/ml; SELco®Tg-assay: 0.5, 1, 2 ng/ml) with the clinical results in respect to the corresponding TSH concentration. Results: Tg concentration did not show any significant difference (SELco®Tg-assay 0.5 ng/ml, Dynotest® Tg-plus 0.2 ng/ml). The Tg-values of both assays correlated with 97%. However, correlation of recovery in both assays was small (40%). The sensitivities and specificities of both assays at different cut-offs and TSH values did not reveal significant differences. In patients with TSH concentration >30 µU/ml the functional assay sensitivity was superior to arbitrary cut-offs in the decision to start further evaluations. Conclusions: In our study neither formal nor clinical significant differences between two Tg-assays were found. In a hypothyroid patient (TSH >30 µU/ml, Tg concentration exceeding the functional assay sensitivity) further investigations for residual disease are warranted. Higher thresholds are of limited value, due to a inacceptable high rate of false negative results.

Sign in / Sign up

Export Citation Format

Share Document